Forest Tudorza Pressair Approval For COPD Includes Post-marketing CV Safety Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The twice-daily aclidinium, a long-acting antimuscarinic agent, should be available to wholesalers in the fourth quarter.
You may also be interested in...
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.
GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement
Pulmonary-Allergy Drugs Advisory Committee votes in favor of what could become the first-approved LAMA/LABA combo for COPD but wants postmarket safety study in patients with more severe cardiovascular disease.
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.